Tamoxifen is not effective for liver cancer patients
Author Information
Author(s): Ciro Gallo, Ermelinda De Maio, Massimo Di Maio, Giuseppe Signoriello, Bruno Daniele, Sandro Pignata, Annalisa Annunziata, Francesco Perrone
Primary Institution: Second University, Naples, Italy
Hypothesis
Tamoxifen might be effective in patients with better prognosis.
Conclusion
Tamoxifen should no longer be considered for the treatment of HCC patients as it does not improve survival.
Supporting Evidence
- Tamoxifen did not improve survival in the Okuda I-II subgroup.
- Median survival times were equal for both treatment arms in the Okuda I-II subgroup.
- No significant survival difference was found in the better CLIP subgroup.
Takeaway
The study found that tamoxifen does not help patients with liver cancer live longer, so doctors shouldn't use it for this disease.
Methodology
The study analyzed data from the phase 3 CLIP-1 trial comparing tamoxifen with supportive therapy, focusing on overall survival.
Potential Biases
Subgroup analyses may exaggerate treatment effects due to multiple comparisons.
Limitations
The study's findings may be limited by the subgroup analyses and the potential for false positives.
Participant Demographics
The study included 496 subjects from 30 Italian institutions, with a mix of genders and ages.
Statistical Information
P-Value
0.501
Confidence Interval
95%CI 12.7–18.5
Statistical Significance
p = 0.501
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website